| Characteristics | Frequency | Percentage (%) |
| Residence (N = 105) |
|
|
| Urban | 68 | 64.8 |
| Rural | 37 | 35.2 |
| Tumour histology (N = 105) |
|
|
| NSIC | 102 | 97.1 |
| Carcinomatous mastitis | 2 | 1.9 |
| ILC | 1 | 1.0 |
| SBR grade (N = 105) |
|
|
| 1 | 18 | 16.8 |
| 2 | 78 | 74.3 |
| 3 | 9 | 8.9 |
| The T category of TNM (N = 105) |
|
|
| T3 | 27 | 25.7 |
| T4a | 5 | 4.8 |
| T4b | 14 | 13.3 |
| T4c | 7 | 6.7 |
| T4d | 52 | 49.5 |
| UICC classification (N = 105) |
|
|
| IIIA | 77 | 73.3 |
| IIIB | 23 | 21.9 |
| IIIC | 5 | 4.8 |
| Molecular subtype (N = 35) |
|
|
| Luminal A | 5 | 14.3 |
| Luminal B | 9 | 25.7 |
| Her2 enriched | 3 | 8.6 |
| Triple negative | 18 | 51.4 |
| NAC Protocols (N = 105) |
|
|
| 4 AC60 + 4 Paclitaxel hebd. | 55 | 52.4 |
| 4 AC60 + 4 Docetaxel | 29 | 27.6 |
| 3 AC60 + 3 Paclitaxel hebd. | 2 | 1.9 |
| 3 AC60 + 3 Docetaxel | 11 | 10.5 |
| 6 FAC60 | 8 | 7.6 |
| Number of cures received (N = 105) |
|
|
| ≤5 | 30 | 28.6 |
| 6 - 8 | 72 | 68.6 |
| ≥9 | 3 | 2.8 |